Detalhe da pesquisa
1.
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
Clin Exp Rheumatol
; 37(6): 937-945, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31025930
2.
ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
Rheumatology (Oxford)
; 55(4): 624-35, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26515959
3.
Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis.
Rheumatol Int
; 33(6): 1447-54, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23179262
4.
Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study.
Rheumatol Ther
; 9(5): 1435-1450, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066750
5.
Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience.
Patient Prefer Adherence
; 8: 1061-71, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25125973